Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

NDV-01

Small molecule · Inhibitor of ribonucleotide reductase and tubulin (TUBB) · developed by Relmada Therapeutics

Phase 3 Most advanced trial
RLMD Developer
1 Registered trials

What is NDV-01?

NDV-01 is a sustained-release intravesical carbomer gel combining gemcitabine and docetaxel, released gradually into the bladder after catheter instillation. Gemcitabine is incorporated into DNA and inhibits ribonucleotide reductase, while docetaxel stabilizes tubulin, causing G2/M arrest. It is being studied in bladder urothelial carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
ribonucleotide reductase, tubulin (TUBB)
Mechanism
Inhibitor of ribonucleotide reductase and tubulin (TUBB)
Pathways
DNA synthesis, microtubule dynamics, apoptosis, angiogenesis
Therapy area
Oncology
Developer
Relmada Therapeutics, Inc. (RLMD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07464145 Phase 3 Bladder (Urothelial, Transitional Cell) Cancer Not yet recruiting RLMD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Bladder (Urothelial, Transitional Cell) CancerUrologic CancerUrothelial Carcinoma BladderUrothelial Carcinoma Recurrent

Other drugs acting on TUBB

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the RLMD page.

Follow RLMD, the company behind NDV-01

See RLMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

RLMD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.